ViaDerma, Inc. Enters into a $250,000 Initial Sales Agreement with Vage Nigeria Ltd.Press Release | 04/24/2018
LOS ANGELES, April 24, 2018 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink:VDRM), is pleased to announce it has entered into a $250,000 initial sales agreement with Vage Nigeria Ltd. (“Vage”), a brand support company specializing in product sourcing.
According to the terms of the agreement, Vage will pay a 50% deposit to ViaDerma upon completion of the registration of Vitastem with the National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria’s equivalent to the FDA. The registration process should be completed within 30 days. The balance of the order will be paid to ViaDerma upon delivery of the product in about 8-10 weeks.
Dr. Christopher Otiko, President of ViaDerma, stated “We are very pleased to be working together with Vage and their CEO, Kunle Craig to provide Vitastem to the people of Nigeria. This is only the first of many orders we expect to receive from Vage going forward.”
Kunle Craig, CEO of Vage Nigeria Ltd., commented, “Vitastem is a wonderful ointment that has exceeded all expectations during our testing. The feedback received and the results we have seen have so far been 100% positive. Infections have cleared up in just 3 days, and leg burns have seen significant improvement within 24 hours of application. I’ve witnessed firsthand the positive results brought upon by Vitastem in wound and skin treatment, and I have become a firm believer in this product. From what I have observed, Vitastem is a revolutionary medication.”
